NASDAQ:AVXL - Anavex Life Sciences Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $3.38 -0.18 (-5.06 %) (As of 05/24/2019 12:01 PM ET)Previous Close$3.56Today's Range$3.3747 - $3.6252-Week Range$1.25 - $4.35Volume141,031 shsAverage Volume337,861 shsMarket Capitalization$166.01 millionP/E RatioN/ADividend YieldN/ABeta2.47 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases. The company's lead drug candidate is ANAVEX 2-73, which has completed Phase 2a clinical trial for Alzheimer's disease; and preclinical clinical trials to treat Parkinson's disease, Rett syndrome, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis. It is also developing ANAVEX 3-71 to treat Alzheimer's disease; ANAVEX 1-41, a sigma-1 agonist; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was founded in 2006 and is based in New York, New York. Receive AVXL News and Ratings via Email Sign-up to receive the latest news and ratings for AVXL and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AVXL Previous Symbol CUSIPN/A CIK1314052 Webhttp://www.anavex.com/ Phone844-689-3939Debt Debt-to-Equity RatioN/A Current Ratio3.23 Quick Ratio3.23Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.29 per share Price / Book11.66Profitability EPS (Most Recent Fiscal Year)($0.39) Net Income$-17,450,000.00 Net MarginsN/A Return on Equity-117.06% Return on Assets-94.17%Miscellaneous Employees13 Outstanding Shares49,115,000Market Cap$166.01 million Next Earnings Date8/8/2019 (Estimated) OptionableOptionable Anavex Life Sciences (NASDAQ:AVXL) Frequently Asked Questions What is Anavex Life Sciences' stock symbol? Anavex Life Sciences trades on the NASDAQ under the ticker symbol "AVXL." How were Anavex Life Sciences' earnings last quarter? Anavex Life Sciences Corp (NASDAQ:AVXL) issued its quarterly earnings results on Wednesday, May, 8th. The biotechnology company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.01. View Anavex Life Sciences' Earnings History. When is Anavex Life Sciences' next earnings date? Anavex Life Sciences is scheduled to release their next quarterly earnings announcement on Thursday, August 8th 2019. View Earnings Estimates for Anavex Life Sciences. What price target have analysts set for AVXL? 3 brokerages have issued 12-month target prices for Anavex Life Sciences' shares. Their forecasts range from $7.00 to $10.00. On average, they anticipate Anavex Life Sciences' stock price to reach $9.00 in the next year. This suggests a possible upside of 165.5% from the stock's current price. View Analyst Price Targets for Anavex Life Sciences. What is the consensus analysts' recommendation for Anavex Life Sciences? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anavex Life Sciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Anavex Life Sciences. What are Wall Street analysts saying about Anavex Life Sciences stock? Here are some recent quotes from research analysts about Anavex Life Sciences stock: 1. According to Zacks Investment Research, "ANAVEX LIFE SCIENCES CORP. is an emerging biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases. The company's proprietary SIGMACEPTOR Discovery Platform involves the rational drug design of compounds that fulfill specific criteria based on unmet market needs and new scientific advances. Selected drug candidates demonstrate high, non-exclusive affinity for sigma receptors, which are involved in the modulation of multiple cellular biochemical signaling pathways. " (5/15/2019) 2. HC Wainwright analysts commented, "We value Anavex on the potential of ANAVEX2-73 in Alzheimer’s disease (AD), Rett syndrome, and Parkinson’s disease dementia (PDD). We use a probability adjusted revenue projection for our therapeutic models. In AD we use just 30%, as the current data set, while encouraging, is small." (10/22/2018) 3. Maxim Group analysts commented, "Anavex reported the June quarter with a net loss of $2.8 million and ended the period with $25.8M in cash, runway into 2H19." (8/9/2018) Has Anavex Life Sciences been receiving favorable news coverage? Media headlines about AVXL stock have been trending positive recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Anavex Life Sciences earned a news impact score of 2.3 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near future. Who are some of Anavex Life Sciences' key competitors? Some companies that are related to Anavex Life Sciences include Geovax Labs (GOVX), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX), STARPHARMA HOLD/S (SPHRY), Pieris Pharmaceuticals (PIRS), Luna Innovations (LUNA), Senomyx (SNMX), BIOQUAL (BIOQ), HedgePath Pharmaceuticals (HPPI), Bioanalytical Systems (BASI), Cleveland BioLabs (CBLI), Vitality Biopharma (VBIO), Tenax Therapeutics (TENX), US Stem Cell (USRM) and Protalex (PRTX). What other stocks do shareholders of Anavex Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Anavex Life Sciences investors own include Inovio Pharmaceuticals (INO), POET Technologies (POETF), Brainstorm Cell Therapeutics (BCLI), Sanchez Energy (SN), CytRx (CYTR), VASCO Data Security International (VDSI), Arch Therapeutics (ARTH), Novavax (NVAX), Energous (WATT) and Geron (GERN). Who are Anavex Life Sciences' key executives? Anavex Life Sciences' management team includes the folowing people: Dr. Christopher U. Missling, Chairman, Pres, CEO & Sec. (Age 53)Ms. Sandra Boenisch, Principal Financial Officer & Treasurer (Age 38)Mr. Stephan Toutain, Sr. VP of Operations (Age 53)Dr. Emmanuel O. Fadiran RPh, Ph.D., Sr. VP of Regulatory AffairsDr. Walter E. Kaufmann, Chief Medical Officer Who are Anavex Life Sciences' major shareholders? Anavex Life Sciences' stock is owned by many different of institutional and retail investors. Top institutional investors include Hikari Power Ltd (0.37%), B. Riley Financial Inc. (0.24%), Tibra Equities Europe Ltd (0.18%), Wells Fargo & Company MN (0.13%), Virtu Financial LLC (0.10%) and AllSquare Wealth Management LLC (0.07%). View Institutional Ownership Trends for Anavex Life Sciences. Which institutional investors are selling Anavex Life Sciences stock? AVXL stock was sold by a variety of institutional investors in the last quarter, including PHH Investments Ltd.. View Insider Buying and Selling for Anavex Life Sciences. Which institutional investors are buying Anavex Life Sciences stock? AVXL stock was purchased by a variety of institutional investors in the last quarter, including B. Riley Financial Inc., Tibra Equities Europe Ltd, Virtu Financial LLC, Hikari Power Ltd, Edge Wealth Management LLC, ExodusPoint Capital Management LP, AllSquare Wealth Management LLC and Charles Schwab Investment Management Inc.. View Insider Buying and Selling for Anavex Life Sciences. How do I buy shares of Anavex Life Sciences? Shares of AVXL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Anavex Life Sciences' stock price today? One share of AVXL stock can currently be purchased for approximately $3.39. How big of a company is Anavex Life Sciences? Anavex Life Sciences has a market capitalization of $166.50 million. The biotechnology company earns $-17,450,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis. Anavex Life Sciences employs 13 workers across the globe. What is Anavex Life Sciences' official website? The official website for Anavex Life Sciences is http://www.anavex.com/. How can I contact Anavex Life Sciences? Anavex Life Sciences' mailing address is 51 W 52ND STREET 7TH FLOOR, NEW YORK NY, 10019. The biotechnology company can be reached via phone at 844-689-3939 or via email at [email protected] MarketBeat Community Rating for Anavex Life Sciences (NASDAQ AVXL)Community Ranking: 3.2 out of 5 ( )Outperform Votes: 295 (Vote Outperform)Underperform Votes: 163 (Vote Underperform)Total Votes: 458MarketBeat's community ratings are surveys of what our community members think about Anavex Life Sciences and other stocks. Vote "Outperform" if you believe AVXL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVXL will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/24/2019 by MarketBeat.com StaffFeatured Article: What is a growth and income fund? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.